SCHEMBL69946

SCHEMBL69946

Cc1cc2c(=O)[nH]c(Cn3cc(CNCc4cccnc4)c(C(F)(F)F)n3)nc2s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
HTR1A P08908 1/20 0.40
HTR7 P34969 1/20 0.40
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 6/20 0.34
HSD17B10 Q99714 1/20 0.34
PDE9A O76083 2/20 0.34
GAA P10253 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
OPRM1 P35372 2/20 0.33
OPRD1 P41143 2/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
TNKS O95271 1/20 0.32
TNKS2 Q9H2K2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10051494 0.88 ALDH1A1 (0.43) ALDH1A1HTR1AHTR7LMNAHTT
SCHEMBL69752 0.85 HTR1A (0.34) ALDH1A1HTR1AHTR7TNKSTNKS2
SCHEMBL15435583 0.80 HTR1A (0.37) ALDH1A1HTR1AHTR7HTTTNKS
SCHEMBL69730 0.80 HTR1A (0.40) ALDH1A1HTR1AHTR7TNKSTNKS2
SCHEMBL70462 0.78 HTR1A (0.41) ALDH1A1HTR1AHTR7HTTTNKS
SCHEMBL68684 0.77 HTR1A (0.40) ALDH1A1HTR1AHTR7LMNAHTT
SCHEMBL69775 0.76 HTR1A (0.38) HTR1AHTR7LMNATNKSTNKS2
SCHEMBL70516 0.73 HTR1A (0.39) ALDH1A1HTR1AHTR7HTTKDM4E
SCHEMBL71000 0.73 HTR1A (0.39) ALDH1A1HTR1AHTR7HTTTNKS
SCHEMBL91609 0.68 HTR1A (0.40) ALDH1A1HTR1AHTR7TNKSTNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2209791-B1 Heterocyclic derivatives MERCK SHARP & DOHME (NL) 2014-01-22 EP disclosed
EP-2209791-B1 Heterocyclic derivatives MERCK SHARP & DOHME (NL) 2014-01-22 EP disclosed
US-8129397-B2 Substituted thieno[2,3-d]pyrimidines as AMPA modulators MSD OSS B.V. (US) 2012-03-06 US disclosed
US-8129397-B2 Substituted thieno[2,3-d]pyrimidines as AMPA modulators MSD OSS B.V. (US) 2012-03-06 US disclosed
WO-2009062930-A1 HETEROCYCLIC DERIVATIVES N.V. ORGANON (NL) 2009-05-22 WO disclosed
US-20090131455-A1 HETEROCYCLIC DERIVATIVES N.V. ORGANON 2009-05-21 US disclosed
US-20090131455-A1 HETEROCYCLIC DERIVATIVES N.V. ORGANON 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131455-A1 HETEROCYCLIC DERIVATIVES GRIN2C, GRIK5, GRIN1 ALDH1A1 398/4885HTR1A 135/4885HTR7 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.